Disease Modifying Glaucoma Treatments and Novel Therapies
Media formats available:
Details
Presenters
Overview
Two new drugs in novel classes were approved recently for IOP reduction in eyes with ocular hypertension or open-angle glaucoma. View this webinar, hosted by two glaucoma experts, to learn more about these new treatments, plus therapeutics pending approval by the FDA. A case series is also included in this presentation.This Activity is supported by an unrestricted educational grant from Aerie. Learning Objectives
Upon completion of this activity, the participant should be able to: - Understand the mechanisms of action of novel trabecular outflow medications.
- Describe the efficacy and safety profiles of novel trabecular outflow medications.
- Demonstrate proficiency in selecting appropriate therapies to achieve individualized patient-specific treatment goals.
Accreditation
Accreditation Statement Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Evolve is an approved COPE Administrator. This course is COPE approved for 1.0 hours of CE Credit for Optometrists. Course #63761-GL COPE Activity ID #117840 Faculty and Disclosures
DISCLOSURE POLICY
DISCLOSURE POLICY It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity. The following faculty/staff members have the following financial relationships with commercial interests:
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.- Jonathan S. Myers, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals; Allergan, Glaukos, and MicroOptx. Grant Research: Aerie Pharmaceuticals, Alcon, Allergan, Diopsys, Glaukos, Haag Streit, Heidelberg Pharma; Merck, Novartis, Zeiss.
- Douglas J. Rhee, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Alcon, Allergan, Ivantis. Grant Research: Allergan, Glaukos, Ivantis. Speaker:Aerie, Bausch & Lomb, Ivantis.
- Erin K. Fletcher, MIT, director of compliance and education; Susan Gallagher-Pecha, director of client services and project management; Cassandra Richards, director of education development, Evolve, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan.
Disclaimer
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, or Aerie. System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!